Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Gastric acid is believed to be an important etiological factor in the pathogenesis of Barrett's esophagus. Pulsatile acid exposure increases cell proliferation in ex vivo Barrrett's tissue and normalization of esophageal pH reverses this. Proton pump inhibitors (PPIs) are the mainstay of therapy in Barrett's esophagus, and have numerous beneficial effects including symptom control, reduction of inflammation, and promotion of the development of squamous islands. However, PPI therapy causes hypergastrinemia and has not prevented recent increase in the incidences of esophageal cancer. Additionally, evidence presented here by Feagins et al. suggests that acid exposure has a p53-mediated, antiproliferative effect on a nondysplastic Barrett's epithelial cell line, an effect that acid suppression might abrogate. These complex pH, inflammation, and growth factor biological interactions can be most reliably tested in large clinical trials with hard end points like cancer conversion or all causes of mortality. Combining the anti-inflammatory effects of acid suppression with aspirin, a nonsteroidal anti-inflammatory agent, is the subject of the AspECT clinical trial, and this may be the future of chemoprevention in Barrett's.

Original publication

DOI

10.1111/j.1572-0241.2006.01033.x

Type

Journal article

Journal

Am J Gastroenterol

Publication Date

01/2007

Volume

102

Pages

21 - 23

Keywords

Anti-Inflammatory Agents, Non-Steroidal, Anti-Ulcer Agents, Aspirin, Barrett Esophagus, Chemoprevention, Evidence-Based Medicine, Gastroesophageal Reflux, Humans, Hydrogen-Ion Concentration, Precancerous Conditions, Proton Pump Inhibitors, Tumor Suppressor Protein p53